tetano
Editor, Senior Moderator
Biochem Biophys Res Commun. 2012 Jul 14. [Epub ahead of print]
Favipiravir (T-705) inhibits in vitro norovirus replication.
Rocha-Pereira J, Jochmans D, Dallmeier K, Leyssen P, Nascimento MS, Neyts J.
Source
Laborat?rio de Microbiologia, Departamento de Ci?ncias Biol?gicas, Faculdade de Farm?cia, Universidade do Porto, Rua de Jorge Viterbo Ferreira n.? 228, 4050-313 Porto, Portugal; Centro de Qu?mica Medicinal da Universidade do Porto (CEQUIMED-UP), Rua de Jorge Viterbo Ferreira n.? 228, 4050-313 Porto, Portugal.
Abstract
Human noroviruses are the primary cause of foodborne gastroenteritis. Potent and safe inhibitors are needed for the treatment /prophylaxis of norovirus infections. We demonstrate that Favipiravir [T-705, a drug in advanced clinical development for the treatment of infections with the influenza virus] inhibits in vitro murine norovirus replication. Time-of-drug addition studies reveal that T-705 exerts its activity at a time-point that coincides with onset of viral RNA synthesis, which is in line with the viral polymerase as the presumed target.
Copyright ? 2012. Published by Elsevier Inc.
PMID:
22809499
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22809499
Favipiravir (T-705) inhibits in vitro norovirus replication.
Rocha-Pereira J, Jochmans D, Dallmeier K, Leyssen P, Nascimento MS, Neyts J.
Source
Laborat?rio de Microbiologia, Departamento de Ci?ncias Biol?gicas, Faculdade de Farm?cia, Universidade do Porto, Rua de Jorge Viterbo Ferreira n.? 228, 4050-313 Porto, Portugal; Centro de Qu?mica Medicinal da Universidade do Porto (CEQUIMED-UP), Rua de Jorge Viterbo Ferreira n.? 228, 4050-313 Porto, Portugal.
Abstract
Human noroviruses are the primary cause of foodborne gastroenteritis. Potent and safe inhibitors are needed for the treatment /prophylaxis of norovirus infections. We demonstrate that Favipiravir [T-705, a drug in advanced clinical development for the treatment of infections with the influenza virus] inhibits in vitro murine norovirus replication. Time-of-drug addition studies reveal that T-705 exerts its activity at a time-point that coincides with onset of viral RNA synthesis, which is in line with the viral polymerase as the presumed target.
Copyright ? 2012. Published by Elsevier Inc.
PMID:
22809499
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22809499